PENTA guidelines for the use of antiretroviral therapy, 2004.
about
When should children with HIV infection be started on antiretroviral therapy?Early antiretroviral therapy and mortality among HIV-infected infantsPlasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimenUnderdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study.Rate of candidiasis among HIV-infected children in Spain in the era of highly active antiretroviral therapy (1997-2008).Risk of triple-class virological failure in children with HIV: a retrospective cohort studyNovel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children.Paediatric HIV--trends & challengesAntiretroviral treatment of HIV infection: Swedish recommendations 2007.Type I interferon-dependent gene MxA in perinatal HIV-infected patients under antiretroviral therapy as marker for therapy failure and blood plasmacytoid dendritic cells depletionA feasibility study of immediate versus deferred antiretroviral therapy in children with HIV infectionTiming of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children.24-Month adherence, tolerance and efficacy of once-a-day antiretroviral therapy with didanosine, lamivudine, and efavirenz in African HIV-1 infected children: ANRS 12103/12167.Incidence and risk factors for first line anti retroviral treatment failure among Ugandan children attending an urban HIV clinic.Management of paediatric HIV-1 resistance.Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tabletsPediatric HIV: new opportunities to treat children.Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis.Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.Serum leptin concentrations and fat redistribution in HIV-1-infected children on highly active antiretroviral therapy.Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program.Effects of highly active antiretroviral therapy on paediatric metabolite levels.Long-term effectiveness of highly active antiretroviral therapy (HAART) in perinatally HIV-infected children in Denmark.Poor health-related quality of life and abnormal psychosocial adjustment in Italian children with perinatal HIV infection receiving highly active antiretroviral treatment.Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission of HIV.
P2860
Q33325580-1CC77F70-3748-44B9-A217-E7D1956A69AFQ34175450-01CF0782-D6E9-4965-B2C6-DD0F6ABD229DQ34498914-B815582F-AA8A-4AC0-A7E2-3A11C39F91AAQ34622948-982896C7-C00B-41F8-B00D-BB764AF27612Q34627658-3C544E3D-89DF-44D1-B1F0-59F655E218F6Q34997180-962AF421-C610-4BE5-B413-1D2BCA0513F1Q35557224-CA70CFBD-836F-4346-9B8B-12C074AD965CQ35770887-32F9C352-4A78-4EFB-B8A0-FF7B46DB9A58Q36852859-CE9D0F15-35F9-4327-8B04-892F4F8C36E9Q36889683-84F5F9D6-4D8B-41FF-AD17-74EA64B8FAF5Q36975397-F74F10B1-D7B5-43D8-8663-BD6435D6B68CQ37194666-CF2426A4-D7B0-4CC9-A0A3-3E4C4ED130C1Q37299209-3066E8AC-ADC3-4CA2-8514-461943E063EFQ37322060-0A27D7A1-EFB2-4117-BA2A-CA921E06ED35Q37326138-8E16C619-37BD-44A7-BD23-39E172EE2514Q37417516-40478808-F9B0-4749-9B08-EC4801536CE1Q37532579-086E9AE3-20AD-4920-B887-76904F1A743AQ38771392-433A00DE-1FD7-4877-886F-F98C0A2643EFQ40050910-696370E7-EAC7-46F4-893B-8050E3C2E645Q43732655-6D6CE2C9-340E-4960-B40A-6BF8D793EC54Q46529554-E14E7ED7-7BFF-4476-B174-B6832491E444Q46824216-D151D56C-2DE4-43E0-9684-34E74616A890Q50545880-A69691A0-90C6-416E-8D4A-8B77C43F7FD9Q51760343-63F0F09E-0253-44FB-AA77-475DA2ABA8FDQ53850313-AF081CED-99BC-4162-8B7E-71CAB9C57A8B
P2860
PENTA guidelines for the use of antiretroviral therapy, 2004.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
PENTA guidelines for the use of antiretroviral therapy, 2004.
@en
PENTA guidelines for the use of antiretroviral therapy, 2004.
@nl
type
label
PENTA guidelines for the use of antiretroviral therapy, 2004.
@en
PENTA guidelines for the use of antiretroviral therapy, 2004.
@nl
prefLabel
PENTA guidelines for the use of antiretroviral therapy, 2004.
@en
PENTA guidelines for the use of antiretroviral therapy, 2004.
@nl
P2093
P2860
P1433
P1476
PENTA guidelines for the use of antiretroviral therapy, 2004.
@en
P2093
G Castelli
M Sharland
PENTA Steering Committee
P2860
P356
10.1111/J.1468-1293.2004.00227.X
P478
P577
2004-07-01T00:00:00Z